5 documents

Read All
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Oncothyreon, Braeburn deal

Oncothyreon granted Braeburn rights to develop and commercialize ATI-9242, a next-generation atypical antipsychotic agent modeled on clozapine that has completed a Phase I trial to treat schizophrenia. Braeburn plans to develop ATI-9242 into a long-acting...
Read More
08:00 , Feb 22, 2010 |  BC Week In Review  |  Company News

ARYx cardiovascular, neurology, gastrointestinal news

ARYx reduced headcount to fewer than 20 and hired Cowen and Co. to explore strategic options after partnering discussions for budiodarone fell through. The anti-arrhythmic amiodarone analog has completed a Phase IIb trial to treat...
Read More
07:00 , Jul 13, 2009 |  BioCentury  |  Product Development

The real world must wait

There some indications where it is hard to get new drugs approved, despite the obvious need, because patients on traditional treatments do so much better in the rigorous setting of a clinical trial than they...
Read More
07:00 , Apr 28, 2008 |  BC Week In Review  |  Clinical News

ATI-9242: Phase I started

ARYx began a double-blind, placebo-controlled Phase I (CLN-901) trial of oral ATI-9242 in healthy volunteers. ARYx Therapeutics Inc. (NASDAQ:ARYX), Fremont, Calif.   Product: ATI-9242   Business: Neurology   Molecular target: NA   Description: Next-generation atypical...
Read More
07:00 , Mar 24, 2008 |  BioCentury  |  Finance

Ebb & Flow Focus

Although big series A rounds have become increasingly commonplace, the recent deal for Albireo AB, expected to reach $40 million, reflects business as usual for...
Read More